1 Multi-steroid profiling by uPLC-MS/MS with post-column infusion of ammonium

- 2 fluoride
- 3 Lina Schiffer¹, Fozia Shaheen¹, Lorna C. Gilligan¹, Karl-Heinz Storbeck^{1,2}, James Hawley³,
- 4 Brian G. Keevil³, Wiebke Arlt^{1,4}, Angela E. Taylor¹
- ⁵ ¹ Institute of Metabolism and Systems Research (IMSR), University of Birmingham,
- 6 Birmingham, UK
- 7 ² Department of Biochemistry, Stellenbosch University, Stellenbosch, South Africa
- ³ Department of Clinical Biochemistry, Wythenshawe Hospital, Manchester NHS Foundation
- 9 Trust, Manchester, UK
- 10 Corresponding author: Dr Angela E Taylor, Institute of Metabolism and Systems
- 11 Research, University of Birmingham, Birmingham B15 2TT, UK. E-mail:
- 12 <u>a.taylor.5@bham.ac.uk</u>

13 Abstract

Background: Multi-steroid profiling is a powerful analytical tool that simultaneously quantifies steroids from different biosynthetic pathways. Here we present an ultra-high performance liquid chromatography-tandem mass spectrometry (uPLC-MS/MS) assay for the profiling of 25 steroids using post-column infusion of ammonium fluoride.

Methods: Following liquid-liquid extraction, steroids were chromatographically separated over 5 minutes using a Phenomenex Luna Omega C₁₈ column and a water (0.1 % formic acid) methanol gradient. Quantification was performed on a Waters Acquity uPLC and Xevo[®] TQ-XS mass spectrometer. Ammonium fluoride (6 mmol/L, post-column infusion) and formic acid (0.1 % (vol/vol), mobile phase additive) were compared as additives to aid ionisation.

23 **Results:** Post-column infusion (PCI) of ammonium fluoride (NH₄F) enhanced ionisation in a 24 steroid structure-dependent fashion compared to formic acid (122-140% for 3βOH-Δ5 25 steroids and 477-1274% for 3-keto-Δ4 steroids). Therefore, we fully analytically validated 26 PCI with NH₄F. Lower limits of quantification ranged from 0.28 to 3.42 nmol/L; 23 of 25 27 analytes were quantifiable with acceptable accuracy (bias range -14% to 11.9%). Average 28 recovery ranged from 91.6% to 113.6% and average matrix effects from -29.9% to 19.9%. 29 Imprecision ranged from 2.3% to 23.9% for all analytes and was <15% for 18/25 analytes. 30 The serum multi-steroid profile of 10 healthy men and 10 healthy women was measured.

Conclusions: uPLC-MS/MS with post-column infusion of ammonium fluoride enables
 comprehensive multi-steroid profiling through enhanced ionisation particularly benefiting the
 detection of 3-keto-Δ4 steroids.

34	Key words:	steroid	quantification,	11-oxygenated	androgens,	liquid ch	romatograph	v-
				,,,	J ,			

35 tandem mass spectrometry, androgens, mineralocorticoids, glucocorticoids.

36		
37 38 39	Highli	ghts (3-5; 85 max. characters)
40 41	•	This multi-steroid profiling assay quantifies 25 steroids in 5.5 minutes
42 43	•	Post-column infusion of NH ₄ F enhances the ionisation of 3-keto- Δ 4 steroids
44 45	•	The assay simultaneously quantifies steroids from several biosynthetic pathways
46 47 48 49	•	We present analytical data validated for serum steroid profiling
50		

51 1. Introduction

52 Steroid hormones are biosynthesised in the adrenal cortex and gonads via cascade-like, 53 interlinked enzymatic pathways and undergo extensive metabolism with both activation and 54 inactivation in peripheral tissues (Figure 1) leading to a complex circulating steroid 55 metabolome [1]. Steroid flux through the different pathways can be severely dysregulated in 56 various conditions, requiring comprehensive steroid assessment to develop a mechanistic 57 understanding of the condition and for diagnosis and treatment monitoring. Disorders of 58 steroidogenesis with distinct steroid metabolome profiles include inborn enzymatic 59 deficiencies such as congenital adrenal hyperplasia, autonomous adrenal steroid production 60 such as Cushing syndrome or primary aldosteronism [2], adrenocortical carcinoma [3, 4], 61 polycystic ovary syndrome and idiopathic intracranial hypertension [5-7]. Steroid-dependent 62 cancers, such as prostate cancer, can locally activate steroids and are treated with various 63 pharmacological or surgical approaches to deplete the relevant steroids and their precursors 64 in circulation [8].

65 Traditionally, individual steroids have been used for the assessment of a suspected 66 underlying condition (e.g. testosterone (T) for female androgen excess [9]; 17a-67 hydroxyprogesterone (170HP) for congenital adrenal hyperplasia [10]). Mechanistic in-vitro 68 studies often rely on the measurement of the end products of a biosynthesis pathway only. 69 However, the determination of a multi-steroid profile has several advantages over the use of 70 selected individual markers. First, steroid precursor/product ratios can be calculated to 71 identify distinct effects on individual enzymes [11] and to assess the degree of steroid 72 precursor activation in conditions of steroid excess. For example, in serum the ratio of T to 73 its less active precursor androstenedione (A4) and the ratio of T to the more potent 74 androgen 5a-dihydrotestosterone (DHT) have been shown to be excellent markers for 75 androgen excess and the associated adverse metabolic phenotype in polycystic ovary 76 syndrome [5, 12, 13]. Secondly, multi-steroid profiling enables different pathways of 77 steroidogenesis to be assessed simultaneously, which is essential due to the interlinked 78 nature of steroidogenesis and the contribution of individual enzymes to several pathways 79 (Figure 1). Thirdly, multi-steroid profiling can be used to investigate off-target effects of 80 inhibitors of steroidogenesis. Finally, multi-steroid profiling can be combined with machine 81 learning approaches to generate powerful, unbiased and automated diagnostic steroid 82 metabolomics tools [3, 4].

In contrast to immunoassays, mass spectrometry allows for multiplexing of analytes and liquid chromatography for the high-throughput that is required to effectively use multi-steroid profiling in clinical and research laboratories. Steroid analysis by mass spectrometry is often limited by poor sensitivity due to low analyte concentrations in biological samples and low ionisation efficiency of the analytes. Mobile phase additives can improve the

88 chromatography (peak separation and shape), enhance the signal and, thereby, sensitivity. 89 Formic (methanoic) acid and acetic acid are common additives for corticosteroids and 90 androgen analysis in the positive ionisation mode [5, 14, 15] as they can promote the 91 formation of protonated molecular ions $(M+H)^+$. Ammonium fluoride (NH_4F) can aid the 92 ionisation of steroids in electrospray ionisation (ESI) in negative mode [16] and hence 93 improve the sensitivity of oestrogen measurements [17, 18]. Additionally, NH₄F has been 94 reported to augment the ionisation of steroids using ESI in positive ion mode in a structure-95 dependent manner, when coupled to supercritical fluid chromatography [19]. Here, we 96 present an ultra-high performance liquid chromatography-tandem mass spectrometry (uPLC-97 MS/MS) assay to measure 25 steroids (Table 1) from the mineralocorticoid, glucocorticoid, 98 androgen, alternative and 11-oxygenated steroidogenic pathways. The separation was 99 achieved in 5 minutes using post-column infusion of NH₄F in positive ionisation mode to 100 enhance ionisation.

101

102 2. Material and methods

2.1 Preparation of external standards and quality controls

104 Pure standards of all analytes were purchased as powders from Sigma-Aldrich (Gillingham, 105 UK) and Steraloids (Newport, USA); for details see Supplemental Table 1. The purity of all 106 standards was confirmed by gas chromatography-mass spectrometry. Individual stock 107 solutions at 1 mg/mL were prepared in uPLC grade methanol (Biosolve, Dieuze, France) and 108 stored at -80 °C. Using the stock solutions, combined calibrators for all analytes were 109 prepared by spiking phosphate buffered saline (PBS) pH 7.4 supplemented with 0.1% 110 (wt/vol) bovine serum albumin (BSA) (Sigma-Aldrich) yielding at least 10 different final 111 concentrations from 0 up to 250 ng/mL (Supplemental Table 2). A combined internal 112 standard stock solution containing 0.5 µg/mL of each internal standard was prepared in 113 deuterated methanol (Sigma-Aldrich).

114 Quality control (QC) samples were prepared by spiking PBS 0.1% BSA from independent 1 115 mg/mL stock solutions. Four different concentrations covering the expected concentration 116 range human serum (Supplemental Table 2). Additionally, pooled human serum (Sigma-117 Aldrich) was aliquoted, stored at -80 °C and used as biological QC in each analytical run. All 118 calibrators, internal standards and QCs were stored at -20 °C.

119 2.2 Collection of serum samples

120 The collection of blood samples was approved by the authors' Institutional Review Board 121 (Science, Technology, Engineering and Mathematics Ethical Review Committee of the 122 University of Birmingham, ERN_17-0494). Informed, written consent was obtained from all 123 individuals included in this study. Following venous puncture, blood was collected into gold

top SST Vacutainers[®] (Becton, Dickinson, Wokingham, UK). Samples were spun and the
serum removed and stored at -80 °C until analysis. The method was applied to 20 serum
samples from healthy volunteers 10 female and 10 males (20-40 years).

127 2.3 Sample preparation

128 Steroids were extracted by liquid-liquid extraction. A set of calibrators, QCs and biological 129 QCs were prepared with each batch of samples. Sample, calibrator, or QC (200 µL) were 130 transferred into a hexamethyldisilazane-treated glass tube and 10 µL of the internal standard 131 mixture containing all stable isotope labelled internal standards listed in Table S1. 50 µL of 132 acetonitrile (Biosolve, Dieuze, FR) was added to precipitate the proteins and the samples 133 were vortexed. 1-mL of tert-butyl methyl ether (Acros Organics, Fisher Scientific UK Ltd, 134 Loughborough, UK) was added to each sample and the samples were vortexed at 1000 rpm 135 for 10 minutes on a multi-vortex. The samples were incubated at room temperature for at 136 least 30 minutes to aid phase separation. The organic phase was subsequently transferred 137 into the wells of a 2-mL square well 96-well plate (Porvair Sciences Ltd, Wrexham, UK) 138 containing 700 µL glass inserts (Randox, Crumlin, UK) and dried under a nitrogen stream at 139 45 °C. The dried extract was reconstituted in 100 µL of 50% (vol/vol) uPLC grade methanol 140 (Biosolve) in uPLC grade water (Biosolve) prior to analysis.

141 **2.4 Ultra-high performance liquid chromatography**

142 Chromatography was performed on an Acquity ultra performance liquid chromatography 143 system (uPLC; Waters Ltd, Wilmslow, UK) using a Phenomenex Luna Omega column, 1.6 144 μm, polar C18, 100 Å, 2.1 x 50 mm; (Phenomenex, Macclesfield, UK) at 60 °C. 10 μL of the 145 reconstituted sample was injected. Mobile phase A consisted of uPLC grade water 146 (Biosolve) and mobile phase B of uPLC grade methanol (Biosolve). An optimised method 147 with a linear gradient from 45% to 75% of mobile phase B was applied over five minutes at a 148 flow rate of 0.6 mL/min to separate the analytes followed by a 98% wash and equilibration at 149 starting conditions prior to the injection of the next sample. The auto sampler was 150 maintained at 10 °C. To investigate ionisation 0.1% (vol/vol) formic acid (added to mobile 151 phase A or both A and B) was compared to PCI of NH₄F.

152 2.5 Tandem mass spectrometry

The uPLC eluate was injected into a XEVO[®] TQ-XS mass spectrometer (Waters Ltd) using ESI in positive ion mode. Post-column infusion 6 mmol/L NH₄F in 50% (vol/vol) was combined using the fluidics system on the mass spectrometer under full software control. The capillary voltage was maintained at 1.5 kV, the source temperature was 150 °C, desolvation temperature and gas flow were 600 °C and 1200 L/h, cone gas was 150 L/h. MassLynx 4.2 software (Waters Ltd) was used for systems control. Qualifier and quantifier mass transitions, cone voltages and collision energies are summarised in Table 2.

160 TargetLynx software was used for data processing and quantification. Peak area ratios of 161 analyte to internal standard were plotted against the nominal concentrations of the 162 calibrators and 1/x weighting and linear least square regression were used to produce the 163 standard curve.

164 2.6 Validation

165 Validation was performed following protocols from published guidelines [20-22]. For each 166 steroid, validation has been performed at different concentrations representing low, medium 167 and high concentrations of that steroid in serum. While this method has utility for many 168 applications, we opted to validate for a serum application. We selected serum because it is a 169 complex mixture of steroids, proteins, salts and many other constituents. These constituents 170 can vary between individuals and can each affect steroid extraction and ionisation 171 efficiencies. In addition, serum contains steroids at a range of concentrations, for example 172 low level poor ionising steroids such as DHT (<0.3 ng/mL (1 nM)) and high concentration 173 good ionisers like cortisol (~18 to 300 ng/mL (50-800 nM)). Optimisation using such a 174 complex matrix means adaptation of this method to other 'cleaner' bio-fluids or cell culture 175 supernatants should be simple.

176 2.6.1 Recovery and matrix effects

Matrix effects and recovery were determined as previously described [23, 24]. Six different human serum samples (four male and two female) were spiked at 5 ng/mL before extraction (pre-extract) and after extraction and reconstitution (post extract). Additionally, the reconstitution solvent (50% (vol/vol) uPLC grade methanol in uPLC grade water) was spiked with the same amounts of analytes (no extract). Percentage matrix effects and recovery were calculated from the concentrations quantified in the samples:

183

Matrix Effects (%)

= (Concentration (post extract) - Concentration (no extract)|Concentration (no extract) x 100

184

185

For matrix effects mean values between -15 and 15% were considered ideal and -20% and 20% were acceptable. For recovery mean values between 80% and 120% were defined acceptable.

189 **2.6.2 Linearity**

190 Three calibration series were prepared by different scientists. For each analyte the ratio of 191 analyte peak area to internal standard peak area was plotted against the nominal

192 concentrations of the standard as described above. Calibration curves were accepted as 193 linear if the correlation coefficient of the linear regression (R^2) was ≥ 0.99 .

194 **2.6.3 Lower limit of quantification**

- 195 The lower limit of quantification (LLOQ) was defined as the lowest concentration for which 10
- 196 replicate samples of spiked surrogate matrix could be run with a CV <20% and a bias not
- 197 greater than $\pm 20\%$.

198 2.6.4 Imprecision

Pooled surrogate matrix samples spiked with all analytes at four different concentrations (0.3, 1, 3 and 30 ng/mL) were run 10 times in the same batch to assess intra-assay imprecision. Pooled serum samples and pooled serum samples spiked with 5 ng/mL for all analytes were also run 10 times in the same batch to assess intra-assay imprecision. These samples were extracted and run-in different batches to assess inter-assay imprecision (n =20). A CV \leq 15% was considered optimal.

205 **2.6.5 Accuracy**

206 10 samples of surrogate matrix were spiked individually at four different concentrations (0.3,

1, 3 and 30 ng/mL). A bias of the observed concentration and the nominal concentration
between -15% and +15% was considered optimal.

209

210 3. Results

211 **3.1 Chromatographic separation**

Analytes were separated using a linear gradient over five minutes followed by 0.5 minutes at starting conditions for equilibration resulting in a total run time injection-to-injection of 5.5 minutes. All analytes eluted as distinct, identifiable peaks (Supplemental Figure 1). Two pairs of analytes co-eluted: (cortisol (m/z 363) and 11KA4 (m/z 301); 17OHP (m/z 330) and 17Preg (m/z 332)). No interference was observed due to the differences in m/z (Table 2).

217 **3.2 Comparison of additives to improve ionisation**

218 The effect of NH₄F on signal intensity was assessed in comparison to our previously 219 published method using 0.1% (vol/vol) formic acid as mobile phase additive in both the 220 methanol and water phases [5, 7]. We chose to add NH₄F by post-column infusion as 221 preliminary experiments with NH₄F as an additive led to increases in system pressure 222 indicative of damage to the column material (data not shown). The intra-assay imprecision 223 using this modification was acceptable with a mean CV of the peak area of 7.0% for all 224 analytes (CV range 3.9 to 13.7%; n=60 injections of the same sample (data not shown)). 225 Peak areas of all analytes in serum (n=73) were compared between the assay with formic 226 acid in both mobile phases and the assay using post-column infusion of NH₄F. NH₄F

227 increased peak area in a structure-dependent fashion (Figure 2, Supplemental Figure 2). In 228 comparison to formic acid, NH₄F induced significant increases in the peak area of steroids 229 with 3-keto-Δ4 structure (Prog, DOC, B, Aldo, 17OHP, S, E, F, A4, 11OHA4, 11KA4, T, 230 11KT, 110HT), with mean increases varying from 477% (170HP) to 1274% (Aldo). NH₄F 231 had a lower impact on the peak area of the majority of A-ring reduced steroids with changes 232 varying between 100% and 381% (DHT, 5a-dione, 3a-diol, An, 5a-DHP, 3a5a17HP), with 233 the exceptions of alloP (841%) and 17OHDHP (1280%). NH₄F post-column infusion had 234 only a very minor impact on the peak areas of 3β -OH- $\Delta 5$ steroids (Preg, 17Preg, DHEA). 235 Our final optimised method employed 6 mmol/L NH₄F introduced via post-column infusion at 236 a flow rate of 5 µL/min, with 0.1% (vol/vol) formic acid in the water mobile phase to limit the 237 risk of microbial contamination.

238 **3.3 Validation of the analytical performance**

239 The analytical performance of the optimised assay with post-column infusion of NH₄F and 240 0.1% (vol/vol) formic acid in mobile phase A was validated. Matrix effects and recovery were 241 assessed for six different serum samples (Table 3). Mean matrix effects ranged from -19.5% 242 to 19.9% for all analytes and were hence in the desired range from -20% to 20%, except for 243 5aDHP (-29.9%), 17OHDHP (-22.6%) and 3a5a17HP (-62.7%). Mean recovery ranged from 244 90.0% to 113.6% for all analytes except for $3\alpha5\alpha17$ HP (122.1%), which was just outside the 245 acceptance range of 80-120%. Calibration curves were linear with an $R^2 \ge 0.99$ for all 246 analytes (Supplemental Table 2). Lower limits of quantification ranged between 0.1 ng/mL 247 (~0.3 nmol/L) and 0.5 ng/mL (~1.5 nmol/L) for all analytes except for 17Preg and 3α -adiol, 248 which had a limit of quantification of 1 ng/mL (corresponding to 3.01 and 3.42 nmol/L, 249 respectively) (Table 3). The accuracy (bias) and imprecision of the assay were assessed 250 with spiked PBS 0.1% BSA samples at four different concentrations. The bias between the 251 observed and nominal concentrations was calculated as a measure of accuracy and the 252 coefficient of variation (CV) as a measure of imprecision (Table 4). Bias was within 253 acceptable limits for the majority of analytes at all concentrations above the LLOQ ranging 254 from -14.0 to 11.9%, with the exception of 5α DHP at 0.3 ng/mL (-21%) and 17OHPreg at 1 255 ng/mL (-17.0%). Imprecision was within acceptable limits for the majority of analytes at 256 concentrations above the LLOQ ranging from 2.3 to 14.7% with the exception of An (15.2% 257 at 0.3 ng/mL), 3α-adiol (17.8% at 1 ng/mL), 17OHPreg (16.5% at 3 ng/mL) and alloP (at all 258 concentrations imprecision ranged from 15.1 to 20.5%).

Additionally, imprecision was assessed using a pooled serum sample (Table 5). The levels in this pooled serum sample were below the limit of quantification for 11 analytes (Preg, Prog, Aldo, DOC, 5α -dione, 3α -adiol, An, 5α DHP, alloP, 17OHDHP, $3\alpha5\alpha17$ HP). For the remaining analytes the intra-assay CV ranged from 2.4 to 16.3% and the inter-assay CV

from 3.5 to 16.1%. For a pooled serum sample spiked with 5 ng/mL of all analytes the intraassay CV was between 2.3% and 12.5% for all analytes. The inter-assay CV was <15% (3.2 to 14.7%) for all steroids except 17OHDHP (17.2%), 3 α -adiol (23.0%), 5 α -DHP (22%) and 3 α 5 α 17HP (23.9%).

267

268

269 **3.4 Serum steroid profiling in healthy volunteers**

270 Following validation, we applied this assay to the measurement of serum samples from 10 271 female (aged 23-39 years) and 10 male healthy volunteers (aged 28-37 years). The highest 272 concentrations were observed for glucocorticoids (F and E), the adrenal androgen precursor 273 DHEA and the mineralocorticoid precursor B. As expected, men had higher levels of T and 274 DHT than women and the levels of all other adrenal derived steroids were similar in men and 275 women (Figure 3). Concentrations of progesterone and its metabolites 5αDHP and alloP 276 were below the LLOQ in men and in 8 of 10 women. 17OHDHP was not detected in any of 277 the samples (Figure 3). The levels of 17Preg quantified in the samples using our assay were 278 notably higher than expected based on our previous reference ranges and publications by 279 other laboratories. While our validation demonstrates that 17Preg can be measured with 280 acceptable precision (Table 4, 5), we conclude that using the assay presented here 17Preg 281 cannot be quantified accurately in serum.

282

283 4. Discussion

284 Multi-steroid profiling provides a wider insight than quantification of a single steroid marker. 285 A multiplexed approach has extensive utility for the diagnosis, monitoring and the 286 development of a mechanistic understanding of steroid-associated conditions as it allows for 287 the integration of steroid flux across all pathways of steroid biosynthesis and metabolism [2, 288 25]. This has led several clinical laboratories to increase the number of analytes that are 289 multiplexed in a single assay [14, 26-28]. Here, we describe the development and validation 290 of an uPLC-MS/MS assay for the simultaneous measurement of 25 steroids from the 291 mineralocorticoid, glucocorticoid, and androgen pathways of steroid biosynthesis with a total 292 run-time of 5.5 minutes.

Formic acid is a standard mobile phase additive for the analysis of steroids in positive ionisation mode as 3-keto- Δ 4 steroids predominantly form protonated molecular ions [M+H]⁺. However, the sensitivity achieved with formic acid as an additive can still be insufficient to accurately quantify the low levels of certain steroids present in serum. Hence, we tested the effect of post-column infusion of NH₄F on the signal of all 25 steroids in our assay and established large increases in peak area for all 3-keto- Δ 4 analytes in the presence of NH₄F

299 compared to formic acid, with lower impact observed on the ionisation of A-ring reduced and 300 3β OH- Δ 5 steroids. These findings are consistent with published results on the effect of NH₄F 301 on the ionisation of selected steroids in a supercritical fluid chromatography set up with ESI 302 in positive mode [19]. 3-keto- $\Delta 4$ steroids predominantly form quasi molecular ions [M+H]⁺ 303 during ESI. Parr et al. [19] speculate that the signal enhancement observed for 3-keto-Δ4 is 304 due to the formation of $[M+H]^+$ ions being aided in the presence of NH_4F , as the proton 305 affinity of 3-keto- $\Delta 4$ steroids is higher than that of ammonia. Another possible mechanism is 306 that F⁻ ions capture potential Na⁺ contaminations in the mobile phases, hence preventing the 307 formation of [M+Na]⁺ adducts.

308 While other assays for steroid analysis by ESI in positive mode use NH₄F as mobile phase 309 additives [18, 29], we chose to supply NH₄F by post-column infusion to allow for cost- and 310 time efficient incorporation of the assay into lab workflows. As indicated by the system 311 pressure increased in our own preliminary experiments with NH₄F in the mobile phase, NH₄F 312 can have detrimental effects on column lifetime [30], which is circumvented by post-column 313 infusion. If running different assays on the same LC-MS/MS system, post-column infusion of 314 additives limits the variability of mobile phase compositions that are used on the system, 315 which could reduce the time needed for equilibration, when switching between assays that 316 require different additives. The use of the in-built fluidics system of the mass spectrometer 317 for the post-column infusion is simple, robust, and fully automated.

The analytical validation of the assay revealed that 23/25 of the analytes can be robustly quantified at typical serum concentrations, while one of the intermediates of the alternative DHT biosynthesis pathway ($3\alpha5\alpha17HP$) and the precursor steroid 17Preg can only be semiquantitatively profiled, although the clinical utility of these steroids has yet to be determined. We applied the assay to serum samples from healthy male and female volunteers thereby demonstrating the utility of the assay.

324 To the best of our knowledge, only two LC-MS/MS assays, which analyse 20 or more 325 steroids in serum or plasma, have been published to date [31, 32]. However, the run-times of 326 these assays (16 minutes [31] and 8 minutes [32]) are significantly longer than that of our 327 assay. Published assays with run-times <6 minutes cover a maximum of 16 analytes [33-36]. 328 Additionally, while other assays focus mainly on adrenal steroids [28, 33, 37-39] or androgen 329 panels [14, 40], our assay comprehensively covers multiple steroid classes (Figure 1). In 330 addition to classic androgens, such as A4 and T, our assay covers the alternative pathway of 331 DHT biosynthesis, which contributes to androgen excess in CAH [41, 42], and the 11-332 oxygenated androgens, which have only recently been shown to have major relevance for 333 the diagnosis and mechanistic understanding of androgen excess conditions [6, 43-45]. 334 Here we explored the application of this method to interrogate the complex matrix of serum.

335 With minimal adaptations this uPLC-MS/MS method can be applied to other matrices such

as bio-fluids (saliva, follicular fluid, micro-dialysis fluid etc.), tissues (adipose, brain, prostate etc.), and *in-vitro* cell/organ culture experiments. These applications would need further validation to determine extraction recovery and matrix effects, but depending on the matrix they could conceivably provide improved accuracy and precision especially at the LLOQ.

340 Our assay has limitations that might be considered to hamper its use in routine clinical 341 laboratories: It uses liquid-liquid extraction, which is inexpensive, but time-consuming and 342 labour-intense, when performed manually, and can be challenging to automate. However, 343 the assay can be adjusted for an extraction technique with higher throughput and better 344 potential for (semi-)automation like supported liquid extraction or C_{18} solid phase extraction, 345 used with satisfying results by other serum multi-steroid assays [14, 28, 39]. Moreover, post-346 column infusion as a mode of additive delivery is not available on all mass spectrometers, 347 where this is the case external pumps can be purchased to enable post-column infusion. 348 Finally, not all analytes in our assay have their own stable isotope-labelled internal standard, 349 which is usually considered a prerequisite to appropriately control for matrix effects and 350 extraction losses and to allow for accurate and precise quantification [27, 46]. At the time this 351 assay was developed, no internal standards were commercially available for 5a-dione, 352 110HT, 5aDHP, 170HDHP or 3a5a17HP. Therefore, quantification was performed using 353 the internal standard eluting closest to the analyte, our validation data proves this approach to be sufficient. Use of customised deuterium- or ¹³C-labelled internal standards is expensive 354 355 but could improve accuracy and imprecision of these analytes.

356

357 **7. Conclusions**

uPLC-MS/MS with post-column infusion of ammonium fluoride enables the high throughput,
 sensitive profiling of 25 steroids. Use of NH₄F significantly increased sensitivity for most
 steroids. The method was analytically validated and applied to human serum.

361

362 **Acknowledgments:** The authors thank the volunteers for the donation of blood samples.

- 363 Research funding: Wellcome Trust (Investigator Award WT209492/Z/17/Z, to W.A.)
- Academy of Medical Sciences UK (Newton Advanced Fellowship NAF004\1002, to K.H.S).
- 365
- 366

367 **References**

[1] L. Schiffer, L. Barnard, E.S. Baranowski, L.C. Gilligan, A.E. Taylor, W. Arlt, C.H.L.
Shackleton, K.H. Storbeck, Human steroid biosynthesis, metabolism and excretion are
differentially reflected by serum and urine steroid metabolomes: A comprehensive review,
The Journal of steroid biochemistry and molecular biology, 194 (2019) 105439.

[2] K.H. Storbeck, L. Schiffer, E.S. Baranowski, V. Chortis, A. Prete, L. Barnard, L.C.
Gilligan, A.E. Taylor, J. Idkowiak, W. Arlt, C.H.L. Shackleton, Steroid Metabolome Analysis
in Disorders of Adrenal Steroid Biosynthesis and Metabolism, Endocrine reviews, 40 (2019)
1605-1625.

[3] W. Arlt, M. Biehl, A.E. Taylor, S. Hahner, R. Libe, B.A. Hughes, P. Schneider, D.J. Smith,
H. Stiekema, N. Krone, E. Porfiri, G. Opocher, J. Bertherat, F. Mantero, B. Allolio, M.
Terzolo, P. Nightingale, C.H. Shackleton, X. Bertagna, M. Fassnacht, P.M. Stewart, Urine
steroid metabolomics as a biomarker tool for detecting malignancy in adrenal tumors, The
Journal of clinical endocrinology and metabolism, 96 (2011) 3775-3784.

381 [4] I. Bancos, A.E. Taylor, V. Chortis, A.J. Sitch, C. Jenkinson, C.J. Davidge-Pitts, K. Lang, S. Tsagarakis, M. Macech, A. Riester, T. Deutschbein, I.D. Pupovac, T. Kienitz, A. Prete, 382 383 T.G. Papathomas, L.C. Gilligan, C. Bancos, G. Reimondo, M. Haissaguerre, L. Marina, M.A. 384 Grytaas, A. Sajwani, K. Langton, H.E. Ivison, C.H.L. Shackleton, D. Erickson, M. Asia, S. 385 Palimeri, A. Kondracka, A. Spyroglou, C.L. Ronchi, B. Simunov, D.A. Delivanis, R.P. 386 Sutcliffe, I. Tsirou, T. Bednarczuk, M. Reincke, S. Burger-Stritt, R.A. Feelders, L. Canu, H.R. 387 Haak, G. Eisenhofer, M.C. Dennedy, G.A. Ueland, M. Ivovic, A. Tabarin, M. Terzolo, M. 388 Quinkler, D. Kastelan, M. Fassnacht, F. Beuschlein, U. Ambroziak, D.A. Vassiliadi, M.W. 389 O'Reilly, W.F. Young, Jr., M. Biehl, J.J. Deeks, W. Arlt, Urine steroid metabolomics for the 390 differential diagnosis of adrenal incidentalomas in the EURINE-ACT study: a prospective test 391 validation study, Lancet Diabetes Endocrinol, 8 (2020) 773-781.

[5] M.W. O'Reilly, A.E. Taylor, N.J. Crabtree, B.A. Hughes, F. Capper, R.K. Crowley, P.M.
Stewart, J.W. Tomlinson, W. Arlt, Hyperandrogenemia predicts metabolic phenotype in
polycystic ovary syndrome: the utility of serum androstenedione, The Journal of clinical
endocrinology and metabolism, 99 (2014) 1027-1036.

[6] M.W. O'Reilly, P. Kempegowda, C. Jenkinson, A.E. Taylor, J.L. Quanson, K.H. Storbeck,
W. Arlt, 11-Oxygenated C19 Steroids Are the Predominant Androgens in Polycystic Ovary
Syndrome, The Journal of clinical endocrinology and metabolism, 102 (2017) 840-848.

399 [7] M.W. O'Reilly, C.S. Westgate, C. Hornby, H. Botfield, A.E. Taylor, K. Markey, J.L.

- Mitchell, W.J. Scotton, S.P. Mollan, A. Yiangou, C. Jenkinson, L.C. Gilligan, M. Sherlock, J.
 Gibney, J.W. Tomlinson, G.G. Lavery, D.J. Hodson, W. Arlt, A.J. Sinclair, A unique androgen
 excess signature in idiopathic intracranial hypertension is linked to cerebrospinal fluid
 dynamics, JCI insight, 4 (2019).
- 404 [8] G. Snaterse, J.A. Visser, W. Arlt, J. Hofland, Circulating steroid hormone variations 405 throughout different stages of prostate cancer, Endocrine-related cancer, 24 (2017) R403-406 r420.

407 [9] D. Lizneva, L. Gavrilova-Jordan, W. Walker, R. Azziz, Androgen excess: Investigations
408 and management, Best practice & research. Clinical obstetrics & gynaecology, 37 (2016) 98409 118.

410 [10] J.W. Honour, 17-Hydroxyprogesterone in children, adolescents and adults, Annals of 411 clinical biochemistry, 51 (2014) 424-440.

412 [11] M.P. Caulfield, T. Lynn, M.E. Gottschalk, K.L. Jones, N.F. Taylor, E.M. Malunowicz,

413 C.H. Shackleton, R.E. Reitz, D.A. Fisher, The diagnosis of congenital adrenal hyperplasia in 414 the newborn by gas chromatography/mass spectrometry analysis of random urine

specimens, The Journal of clinical endocrinology and metabolism, 87 (2002) 3682-3690.

- 416 [12] J. Munzker, D. Hofer, C. Trummer, M. Ulbing, A. Harger, T. Pieber, L. Owen, B. Keevil,
- 417 G. Brabant, E. Lerchbaum, B. Obermayer-Pietsch, Testosterone to dihydrotestosterone ratio
- 418 as a new biomarker for an adverse metabolic phenotype in the polycystic ovary syndrome,
- The Journal of clinical endocrinology and metabolism, 100 (2015) 653-660.

[13] J. Munzker, L. Lindheim, J. Adaway, C. Trummer, E. Lerchbaum, T.R. Pieber, B. Keevil,
B. Obermayer-Pietsch, High salivary testosterone-to-androstenedione ratio and adverse
metabolic phenotypes in women with polycystic ovary syndrome, Clinical endocrinology, 86

423 (2017) 567-575.

[14] J.M. Hawley, J.E. Adaway, L.J. Owen, B.G. Keevil, Development of a total serum
testosterone, androstenedione, 17-hydroxyprogesterone, 11beta-hydroxyandrostenedione
and 11-ketotestosterone LC-MS/MS assay and its application to evaluate pre-analytical
sample stability, Clinical chemistry and laboratory medicine, DOI 10.1515/cclm-20190959(2020).

- 429 [15] Y.-C. Ma, H.-Y. Kim, Determination of Steroids by Liquid Chromatography/Mass 430 Spectrometry, Journal of the American Society for Mass Spectrometry, 8 (1997) 1010-1020.
- [16] N.S. Rannulu, R.B. Cole, Novel Fragmentation Pathways of Anionic Adducts of Steroids
 Formed by Electrospray Anion Attachment Involving Regioselective Attachment,
 Regiospecific Decompositions, Charge-Induced Pathways, and Ion–Dipole Complex
 Intermediates, Journal of the American Society for Mass Spectrometry, 23 (2012) 15581568.
- 436 [17] L.J. Owen, F.C. Wu, B.G. Keevil, A rapid direct assay for the routine measurement of
- 437 oestradiol and oestrone by liquid chromatography tandem mass spectrometry, Annals of
 438 clinical biochemistry, 51 (2014) 360-367.
- [18] S.W. Blue, A.J. Winchell, A.V. Kaucher, R.A. Lieberman, C.T. Gilles, M.N. Pyra, R.
 Heffron, X. Hou, R.W. Coombs, K. Nanda, N.L. Davis, A.P. Kourtis, J.T. Herbeck, J.M.
 Baeten, J.R. Lingappa, D.W. Erikson, Simultaneous quantitation of multiple contraceptive
 hormones in human serum by LC-MS/MS, Contraception, 97 (2018) 363-369.
- [19] M.K. Parr, B. Wüst, J. Teubel, J.F. Joseph, Splitless hyphenation of SFC with MS by
 APCI, APPI, and ESI exemplified by steroids as model compounds, Journal of
 Chromatography B, 1091 (2018) 67-78.
- 446 [20] J.W. Honour, Development and validation of a quantitative assay based on tandem 447 mass spectrometry, Annals of clinical biochemistry, 48 (2011) 97-111.
- [21] U.S. Department of Health and Human Services Food and Drug Administration
 Analytical Procedures and Methods Validation for Drugs and Biologics Guidance for
 Industry, DOI (2018).
- 451 [22] B.J. Linnet K, Selection and analytical evaluation of methods with statistical 452 techniques., in: A.E. Burtis CA, Bruns DE (Ed.) Tietz textbook of clinical chemistry and 453 molecular diagnostics, Saunders, St. Louis, 2006, pp. 353-407.
- 454 [23] P.J. Taylor, Matrix effects: the Achilles heel of quantitative high-performance liquid
 455 chromatography-electrospray-tandem mass spectrometry, Clinical biochemistry, 38 (2005)
 456 328-334.
- 457 [24] T.M. Annesley, Ion suppression in mass spectrometry, Clinical chemistry, 49 (2003)458 1041-1044.
- [25] C. Shackleton, O.J. Pozo, J. Marcos, GC/MS in Recent Years Has Defined the Normal
 and Clinically Disordered Steroidome: Will It Soon Be Surpassed by LC/Tandem MS in This
 Role?, Journal of the Endocrine Society, 2 (2018) 974-996.
- 462 [26] N. Janzen, S. Sander, M. Terhardt, M. Peter, J. Sander, Fast and direct quantification of
- adrenal steroids by tandem mass spectrometry in serum and dried blood spots, Journal of
 Chromatography B, 861 (2008) 117-122.
- 465 [27] B.G. Keevil, Novel liquid chromatography tandem mass spectrometry (LC-MS/MS)
 466 methods for measuring steroids, Best practice & research. Clinical endocrinology &
 467 metabolism, 27 (2013) 663-674.
- 468 [28] S. Schweitzer, M. Kunz, M. Kurlbaum, J. Vey, S. Kendl, T. Deutschbein, S. Hahner, M.
 469 Fassnacht, T. Dandekar, M. Kroiss, Plasma steroid metabolome profiling for the diagnosis of
 470 adrenocortical carcinoma, European journal of endocrinology, 180 (2019) 117-125.
- 471 [29] C. Wright, P. O'Day, M. Alyamani, N. Sharifi, R.J. Auchus, Abiraterone acetate
- treatment lowers 11-oxygenated androgens, European journal of endocrinology, 182 (2020)
- 473 413-421.

474 [30] J.J. Pesek, M.T. Matyska, Ammonium fluoride as a mobile phase additive in aqueous
475 normal phase chromatography, Journal of chromatography. A, 1401 (2015) 69-74.

476 [31] M.R. Hakkinen, T. Murtola, R. Voutilainen, M. Poutanen, T. Linnanen, J. Koskivuori, T.

477 Lakka, J. Jaaskelainen, S. Auriola, Simultaneous analysis by LC-MS/MS of 22 ketosteroids

478 with hydroxylamine derivatization and underivatized estradiol from human plasma, serum

and prostate tissue, Journal of pharmaceutical and biomedical analysis, 164 (2019) 642-652.
[32] Z. Wang, H. Wang, Y. Peng, F. Chen, L. Zhao, X. Li, J. Qin, Q. Li, B. Wang, B. Pan, W.

481 Guo, A liquid chromatography-tandem mass spectrometry (LC-MS/MS)-based assay to 482 profile 20 plasma steroids in endocrine disorders, Clinical chemistry and laboratory 483 medicine, DOI 10.1515/cclm-2019-0869(2020).

484 [33] G. Karvaly, K. Kovacs, K. Meszaros, I. Kocsis, A. Patocs, B. Vasarhelyi, The
485 comprehensive characterization of adrenocortical steroidogenesis using two-dimensional
486 ultra-performance liquid chromatography - electrospray ionization tandem mass
487 spectrometry, Journal of pharmaceutical and biomedical analysis, 153 (2018) 274-283.

[34] U. Ceglarek, L. Kortz, A. Leichtle, G.M. Fiedler, J. Kratzsch, J. Thiery, Rapid
quantification of steroid patterns in human serum by on-line solid phase extraction combined
with liquid chromatography-triple quadrupole linear ion trap mass spectrometry, Clinica
chimica acta; international journal of clinical chemistry, 401 (2009) 114-118.

[35] A. Gaudl, J. Kratzsch, Y.J. Bae, W. Kiess, J. Thiery, U. Ceglarek, Liquid
chromatography quadrupole linear ion trap mass spectrometry for quantitative steroid
hormone analysis in plasma, urine, saliva and hair, Journal of chromatography. A, 1464
(2016) 64-71.

496 [36] S. Matysik, G. Liebisch, Quantification of steroid hormones in human serum by liquid
497 chromatography-high resolution tandem mass spectrometry, Journal of chromatography. A,
498 1526 (2017) 112-118.

[37] D.R. Taylor, L. Ghataore, L. Couchman, R.P. Vincent, B. Whitelaw, D. Lewis, S. DiazCano, G. Galata, K.M. Schulte, S. Aylwin, N.F. Taylor, A 13-Steroid Serum Panel Based on
LC-MS/MS: Use in Detection of Adrenocortical Carcinoma, Clinical chemistry, 63 (2017)
1836-1846.

[38] A.S. Boggs, J.A. Bowden, T.M. Galligan, L.J. Guillette, Jr., J.R. Kucklick, Development
of a multi-class steroid hormone screening method using Liquid Chromatography/Tandem
Mass Spectrometry (LC-MS/MS), Analytical and bioanalytical chemistry, 408 (2016) 41794190.

[39] M. Peitzsch, T. Dekkers, M. Haase, F.C. Sweep, I. Quack, G. Antoch, G. Siegert, J.W.
Lenders, J. Deinum, H.S. Willenberg, G. Eisenhofer, An LC-MS/MS method for steroid
profiling during adrenal venous sampling for investigation of primary aldosteronism, The
Journal of steroid biochemistry and molecular biology, 145 (2015) 75-84.

511 [40] L.J. Owen, F.C. Wu, R.M. Buttler, B.G. Keevil, A direct assay for the routine 512 measurement of testosterone, androstenedione, dihydrotestosterone and 513 dehydroepiandrosterone by liquid chromatography tandem mass spectrometry, Annals of 514 clinical biochemistry, 53 (2016) 580-587.

515 [41] C. Kamrath, Z. Hochberg, M.F. Hartmann, T. Remer, S.A. Wudy, Increased activation of 516 the alternative "backdoor" pathway in patients with 21-hydroxylase deficiency: evidence from 517 urinary steroid hormone analysis, The Journal of clinical endocrinology and metabolism, 97 518 (2012) E367-375.

[42] N. Reisch, A.E. Taylor, E.F. Nogueira, D.J. Asby, V. Dhir, A. Berry, N. Krone, R.J.
Auchus, C.H.L. Shackleton, N.A. Hanley, W. Arlt, Alternative pathway androgen biosynthesis
and human fetal female virilization, Proc Natl Acad Sci U S A, 116 (2019) 22294-22299.

[43] A.F. Turcu, A.T. Nanba, R. Chomic, S.K. Upadhyay, T.J. Giordano, J.J. Shields, D.P.
Merke, W.E. Rainey, R.J. Auchus, Adrenal-derived 11-oxygenated 19-carbon steroids are
the dominant androgens in classic 21-hydroxylase deficiency, European journal of
endocrinology, 174 (2016) 601-609.

526 [44] I. Bacila, J. Adaway, J. Hawley, S. Mahdi, R. Krone, L. Patel, S. Alvi, T. Randell, E.

- 527 Gevers, M. Dattani, T. Cheetham, A. Kyriakou, L. Schiffer, F. Ryan, E. Crowne, J.H. Davies,
- 528 S.F. Ahmed, B. Keevil, N. Krone, Measurement of Salivary Adrenal-Specific Androgens as

- 529 Biomarkers of Therapy Control in 21-Hydroxylase Deficiency, The Journal of clinical 530 endocrinology and metabolism, 104 (2019) 6417-6429.
- [45] C. Kamrath, L. Wettstaedt, C. Boettcher, M.F. Hartmann, S.A. Wudy, Androgen excess
 is due to elevated 11-oxygenated androgens in treated children with congenital adrenal
- 533 hyperplasia, The Journal of steroid biochemistry and molecular biology, 178 (2018) 221-228.
- 534 [46] K.M. Wooding, R.J. Auchus, Mass spectrometry theory and application to adrenal
- diseases, Molecular and cellular endocrinology, 371 (2013) 201-207.

537 Tables

538

539 Table 1: Nomenclature of the 25 steroids analysed in this uPLC-MS/MS assay

Steroid abbreviation	Trivial name	Chemical name	Functional class
Preg	Pregnenolone	5-pregnene-3β-ol-20-one	General steroid precursor
Prog	Progesterone	4-pregnene-3,20-dione	Progestogen/general steroid precurso
DOC	11-deoxycorticosterone	4-pregnene-21-ol-3,20-dione	Mineralocorticoid precursor
В	Corticosterone	4-pregnene-11β,21-diol-3,20-dione	Mineralocorticoid precursor
Aldo	Aldosterone	4-pregnene-11β,21-diol-3,20-dione- 18-al	Mineralocorticoid
17Preg	17α-hydroxypregnenolone	5-pregnene-3β,17α-diol-20-one	Glucocorticoid or androgen precursor
17OHP	17α-hydroxyprogesterone	4-pregnene-17β-ol-3,20-dione	Glucocorticoid precursor
S	11-deoxycortisol	4-pregnene-17α,21-diol-3,20-dione	Glucocorticoid precursor
F	Cortisol	4-pregnene-11β,17α,21-triol-3,20- dione	Glucocorticoid
E	Cortisone	4-pregnene-17α,21-diol-3,11,20-trione	Glucocorticoid metabolite
DHEA	Dehydroepiandrosterone	5-androstene-3β-ol-17-one	Classic androgen precursor
A4	Androstenedione	4-androstene-3,17-dione	Classic androgen precursor
Т	Testosterone	4-androstene-17β-ol-3-one	Classic androgen
DHT	5a-dihydrotestosterone	5α-androstane-17β-ol-3-one	Classic androgen
5α-dione	5α-androstanedione	5α-androstane-3,17-dione	Classic androgen metabolite
3α-adiol	5α-androstanediol	5α-androstane-3α,17β-diol	Classic androgen metabolite/alternative DHT pathway intermediate

An	5α-androsterone	5α-androstane-3α-ol-17-one	Classic androgen metabolite/alternative DHT pathway intermediate
11KA4	11-ketoandrostenedione	4-androstene-3,11,17-trione	11-oxygenated androgen precursor
11KT	11-ketotestosterone	4-androstene-17β-ol-3,11-dione	11-oxygenated androgen
110HA4	11β-hydroxyandrostenedione	4-androstene-11β-ol-3,17-dione	11-oxygenated androgen precursor
110HT	11β-hydroxytestosterone	4-androstene-11β,17β-diol-3-one	11-oxygenated androgen
5αDHP	5α-dihydroprogesterone	5α-pregnane-3,20-dione	Progestogen metabolite /alternative DHT pathway intermediate
AlloP	Allopregnanolone	5α-pregnane-3α-ol-20-one	Progestogen metabolite/alternative DHT pathway intermediate
17OHDHP	17α-hydroxy-5α- dihydroprogesterone	5α-pregnane-17α-ol-3,20-dione	Progestogen metabolite/alternative DHT pathway intermediate
3α5α17ΗΡ	17α-hydroxyallopregnanolone (or 5α,17α-hydroxypregnanolone)	5α-pregnane-3α,17α-diol-20-one	Alternative DHT pathway intermediate

Table 2: Retention times, quantifier and qualifier mass transitions, collision energies
 and cone voltages of target analytes and internal standards.

Analyte	Retention time (min)	Mass transition (m/z) Quantifier <i>Qualifier</i>	Cone voltage (V)	Collision energy (eV)
Preg	3.65	299.2 > 281.1 217.1 > 281.1	36	12
Prog	3.37	315.1 > 97.1 315.1 > 100.1	20	20
DOC	2.21	331.1 >97.1 331.1 >109.1	26	20
В	1.52	347.2 > 121.1 347.2 > 97.1	20 20 16	24 20
Aldo	0.86	361.2> 343.2 361.2 > 315.1	40 40	16 18
17Preg	2.42	315.2 > 297.2 297.2 > 279.2	8	12 14
170HP	2.45	331.1 > 97.1 331.1 > 109.1	16 16	22 26
S	1.64	347.1 > 109.1 347.1 > 97.1	42 42	26 22
F	1.06	363.3 > 121.1 363.1 > 91.1	42 42	22 50
E	0.96	361.1 > 163.1 361.1 > 121.01	46 46	22 38
DHEA	2.35	271.2 > 253.2 289.2 > 253.2	30 12	10 8
A4	2.03	287.2 > 109.1 287.2 > 97.1	26 26	22 22
Т	2.26	289.2 > 97.1 289.2 > 109.1	40 40	20 24
DHT	2.80	291.2 > 255.1 291.2 > 159.1	42 42	14 22
5α-dione	2.63	289.2 > 253.1 289.2 > 271.1	40 40	16 10
3α-adiol	3.21	275.2 > 257 275.2 > 81	28 28	10 28
An	3.34	291.2 > 273.2 291.2 > 255.2	24 24	8 12
11KA4	1.06	301.1 >121.1 301.1 > 257.1	44 44	22 22
11KT	1.21	303.1 >121 303.1 > 259.1	20 20	22 22
110HA4	1.34	303.1 > 285.1 303.1 > 267.1	30 30	14 16
110HT	1.48	305.2 > 269.2 305.2 > 121.1	16 16	14 20
5αDHP	4.01	317.1 > 281.1 317.1 > 85.1	38 24	12 14
alloP	4.33	319.1 > 301.2 319.1 > 283.2	22 22	8 14

Internal standard	Retention time (min)	Mass transition (m/z) Quantifier <i>Qualifier</i>	Cone voltage (V)	Collision energy (eV)
170HDHP	2.95	333.2 > 297.2 315.1 > 111	26 32	14 16
3α5α17HP	3.85	317.2 > 299.2 317.2 > 111	28 28	12 18
Preg-d2- ¹³ C2	3.64	321.1 > 303.1	28	8
Prog-d9	3.34	324.2 > 100.1	28	24
DOC-d8	2.18	339.1 > 100.1	26	24
B-d8	1.49	355.1 > 337.2	46	14
Aldo-d8	0.85	369.2 > 351.1	34	16
17Preg-d3	2.4	336.2 > 300.2	12	10
17OHP-d8	2.42	339.1 > 100.1	26	24
S-d2	1.62	349.1 > 97.1	42	22
F-d4	1.06	367.2 > 121.1	28	26
E-d7	0.95	369.1 > 169.1	40	24
DHEA-d6	2.33	277.2 > 219.1	22	14
A4-d7	2.01	294.2 > 109.1	26	22
T-d3	2.25	292.2 > 97.1	46	22
DHT-d3	2.79	294.1 > 258.1	22	16
3α-adiol-d3	3.20	278.2 >150.2	20	20
An-d4	3.33	295.1 > 277.2	24	12
11K4-d10	1.04	311 > 265	46	16
11KT-d3	1.20	306.2 > 262.1	20	22
110HA4-d7	1.30	310.1 > 292.1	30	14
5aDHP-d4	3.96	323.1 > 305.1	22	8
alloP-d4	4.31	323.1 > 305.1	22	8

545

Table 3: Validation summary of matrix effects, recovery and lower limits of quantification for all steroids. Matrix effects and recovery were assessed at 5 ng/mL (approximately 17 nmol/L) in serum samples from six different donors. The lower limit of quantification (LLOQ) was defined as the lowest concentration that can be assessed with appropriate accuracy (bias within \pm 20%) and imprecision (CV < 20%).

552

Analyte	Matrix effects (%)	Recovery (%)	LLOQ	LLOQ
	mean (min-max)	mean (min-max)	(ng/mL)	(nmol/L)
Preg	19.9 (-0.4 - 43.8)	93.9 (75.3-110)	0.2	0.6
Prog	7.4 (-8.2 - 19.7)	98.9 (91.3-110)	0.1	0.3
DOC	14.4 (9.1-20.9)	113.6 (102.9-131.4)	0.2	0.5
В	13.5 (5.3-22.5)	91.3 (74.3-110.3)	0.1	0.3
Aldo	12.6 (8.7-17.5)	103.5 (92.4-111.8)	0.2	0.4
17Preg	-15.9 (-57.9-27.8)	105.5 (59.0-129.7)	1.0	3.0
170HP	-11.4 (-31.3-24.2)	94.5 (78.0-108.6)	0.2	0.6
S	4.3 (-5.0-14.4)	99.9 (88.3-107.9)	0.2	0.4
F	-19.5 (-32.5-16.7	101.7 (7.5-108.4)	0.1	0.3
E	7.1 (-4.3-19.9)	100.7 (95.7-102.8)	0.1	0.3
DHEA	-1.4 (-20.1-12.9)	105.1 (95.0-118.2)	0.2	0.7
A4	12.7 (0.3-29.0)	95.2 (85.8-112.0)	0.2	0.7
Т	0.5 (-8.3-4.9)	102.8 (97.9-106.7)	0.1	0.4
DHT	2.4 (-9.0-10.0)	102.7 (96.6-111.7)	0.1	0.3
5α-dione	19.2 (7.8-29.7)	104.6 (88.6-113.9)	0.2	0.5
3α-adiol	4.2 (-44.1-32.8)	109.1 (96.4-138.8)	1.0	3.4
An	13.0 (5.9-23.0)	98.1 (87.0-107)	0.2	0.7
11KA4	-2.6 (-25.4-33.6)	109.0 (77.3-133.9)	0.1	0.3
11KT	10.1 (4.7-16.6)	98.0 (89.3-102.1)	0.1	0.3
110HA4	-3.6 (-17.4-17.2)	105.9 (94.1-117.8)	0.1	0.3
110HT	1.7 (-6.7-6.1)	101.8 (96.5-110.2)	0.1	0.3
5αDHP	-29.9 (-49.98.4)	113.3 (80.9-184.4)	0.2	0.6
alloP	16.0 (-22.3-40.6)	91.6 (74.0-124.1)	0.2	0.6
17OHDHP	-22.6 (-32.73.0)	90.0 (73.5-101.7)	0.5	1.5
3α5α17HP	-62.7 (-77.245.4)	122.1 (69.2-154.7)	0.5	1.5

553

		Bias (%)			Imprecision (%)			
Concentration (ng/mL)	0.3	1	3	30	0.3	1	3	30
Preg	-9.6	-0.4	-1.4	-3.9	8.0	5.4	13.1	4.6
Prog	-6.2	1.6	1.3	-5.0	7.0	5.3	9.1	3.3
DOC	-0.7	-2.0	3.3	-0.2	7.4	7.6	11.6	6.0
В	-5.4	-6.5	-1.8	9.2	9.4	5.8	12.1	4.8
Aldo	-7.7	-2.1	0.1	0.8	7.0	5.1	9.6	5.0
17Preg	n/a	-17	3.8	-3.6	n/a	10.4	16.5	11.1
17OHP	4.9	-0.2	-5.6	0.2	5.7	10.0	9.4	6.2
S	8.4	3.9	6.8	1.8	5.5	4.8	8.3	3.8
F	2.6	7.7	10.3	2.7	5.5	4.9	4.1	2.3
E	0.7	4.7	7.2	5.0	6.7	4.5	8.2	4.3
DHEA	10.6	4.8	0.6	2.3	13.3	10.1	8.0	3.8
A4	6.1	-5.1	-0.4	-4.6	11.3	8.2	6.9	3.7
Т	-1.8	5.3	7.5	0.6	7.6	5.6	8.2	3.8
DHT	1.3	6.4	10.2	11.9	6.7	5.1	8.4	3.2
5α-dione	-2.2	2.0	3.4	-8.0	7.8	9.5	11.2	8.0
3α-adiol	n/a	4.4	-6.1	2.5	n/a	17.8	11.5	6.5
An	2.5	1.8	-0.5	-2.9	15.2	12.2	9.1	3.5
11KA4	-9.8	-5.7	-0.5	-0.9	8.3	6.1	11.2	5.3
11KT	-8.5	0.5	2.3	-1.6	10.5	4.8	11.6	2.7
110HA4	-4.1	1.6	2.8	-1.9	6.8	5.7	7.5	3.6
11OHT	0.2	5.6	10.9	4.0	11.6	6.8	8.0	5.0
5αDHP	-21.0	-8.2	-3.4	-4.6	14.3	12.5	11.6	14.4
alloP	-14.0	-10.7	-14.0	-11.5	20.5	16.1	15.7	15.1
17OHDHP	n/a	4.3	9.1	6.6	n/a	14.7	6.5	11.6
3α5α17HP	n/a	3.5	7.5	2.0	n/a	9.4	11.0	4.8

555 **Table 4: Accuracy and intra-assay imprecision determined at four concentrations** 556 **spiked into surrogate matrix (n=10).** n/a, not applicable as concentration <LLOQ.

557

559 Table 5: Intra- and inter-assay precision of a pooled serum sample and a pooled

560 serum sample spiked with 5 ng/mL of all analytes. (n=10). n/a, not applicable as

561 concentration below the lower limit of quantification (<LLOQ).

		Pooled serun	า	Pooled serum s	piked at 5 ng/mL	
Analyte	Mean (ng/mL)	lnter- lı assay a -) CV (%) C		Inter-assay CV (%)	Intra-assay CV (%)	
Preg	<lloq< td=""><td>n/a</td><td>n/a</td><td>8.2</td><td>4.9</td></lloq<>	n/a	n/a	8.2	4.9	
Prog	<lloq< td=""><td>n/a</td><td>n/a</td><td>10.8</td><td>12.5</td></lloq<>	n/a	n/a	10.8	12.5	
DOC	<lloq< td=""><td>n/a</td><td>n/a</td><td>5.9</td><td>2.7</td></lloq<>	n/a	n/a	5.9	2.7	
В	2.3	11.2	7.3	12.5	3.7	
Aldo	<lloq< td=""><td>n/a</td><td>n/a</td><td>5.6</td><td>3.7</td></lloq<>	n/a	n/a	5.6	3.7	
17Preg	4.8	16.1	16.3	14.7	8.1	
170HP	1.2	5.5	4.2	12.1	4.5	
S	0.2	8.1	6.9	5.8	3.5	
F	75.2	3.5	2.4	3.7	2.5	
E	9.7	4.2	3.4	4.5	3.1	
DHEA	2.0	6.5	6.0	6.4	6.1	
A4	0.6	15.3	8.0	9.8	9.0	
Т	4.0	4.7	3.5	3.2	2.3	
DHT	0.4	7.5	5.4	5.4	4.1	
5α-dione	<lloq< td=""><td>n/a</td><td>n/a</td><td>12.8</td><td>6.1</td></lloq<>	n/a	n/a	12.8	6.1	
3α-adiol	<lloq< td=""><td>n/a</td><td>n/a</td><td>23.0</td><td>10.0</td></lloq<>	n/a	n/a	23.0	10.0	
An	<lloq< td=""><td>n/a</td><td>n/a</td><td>4.0</td><td>2.8</td></lloq<>	n/a	n/a	4.0	2.8	
11KA4	0.2	16.0	16.2	8.0	6.0	
11KT	0.1	10.1	5.9	4.7	3.0	
110HA4	1.3	12.7	10.2	9.5	5.1	
110HT	0.1	14.9	8.2	5.3	3.2	
5αDHP	<lloq< td=""><td>n/a</td><td>n/a</td><td>22</td><td>4.1</td></lloq<>	n/a	n/a	22	4.1	
alloP	<lloq< td=""><td>n/a</td><td>n/a</td><td>8.1</td><td>6.1</td></lloq<>	n/a	n/a	8.1	6.1	
170HDHP	<lloq< td=""><td>n/a</td><td>n/a</td><td>17.2</td><td>7.0</td></lloq<>	n/a	n/a	17.2	7.0	
3α5α17HP	<lloq< td=""><td>n/a</td><td>n/a</td><td>23.9</td><td>4.2</td></lloq<>	n/a	n/a	23.9	4.2	

37 I

573 Figure legends

Figure 1: Pathways of adrenal steroidogenesis (A) and androgen biosynthesis (B). General steroid precursors are shown in yellow, mineralocorticoids in green, glucocorticoids in orange, androgens in blue. Dark shades of each colour indicate active steroids, light shades inactive precursors. Abbreviations for steroids included in the uPLC-MS/MS assay are shown in bold.

579

580 Figure 2: Ammonium fluoride (NH₄F) post-column infusion enhances ionisation of 581 steroids in a structure-dependent fashion as compared to mobile phase formic acid. 582 The percentage increase in peak area of the quantifier transition when comparing post-583 column infusion of NH₄F (6 mmol/L, 5 µL/min) to the use of 0.1% (vol/vol) formic acid in both 584 the methanol and water mobile phase. Bars represent the mean percentage peak area and 585 whiskers the relative standard deviation for serum samples from different individuals. 586 Samples from all individuals with detectable peaks were included (Prog, DOC, B, 17Preg, 587 170HP, S, F, E, DHEA, A4, T, DHT, An, 11KA4, 11KT, 110HA4, 110HT n=74; Preg n=73; 588 Aldo n=71; 3α-adiol n=56; 5α-DHP n=48; 17OHDHP n=39; 3α5α17HP n=18; alloP n=15; 5α-589 dione n=14). The red line indicates a relative peak area of 100% (identical ionisation with 590 both methods). The colour of the bars indicates the functional class of each analyte; yellow, 591 general steroid precursor; light green, mineralocorticoid precursor; dark green, 592 mineralocorticoid; orange, glucocorticoid precursor; red, glucocorticoid; turquoise, androgen 593 precursor; dark blue, androgen; light blue, alternative DHT biosynthesis pathway 594 intermediate.

595

Figure 3: Human Serum Steroid Profiles. Serum steroid profiles in healthy volunteers, female (red circles; n=10, age range 20-40 years) and male (blue circles, n=10, age range 30-40 years). Each symbol represents one participant; values <LLOQ are represented by open circles and undetectable levels were not included in the visualisation. 17OHDHP was undetectable in any of the samples.

- 601
- 602
- 603
- 604
- 605





